IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
書誌事項
- 公開日
- 2016-11
- 権利情報
-
- https://www.elsevier.com/tdm/userlicense/1.0/
- https://www.elsevier.com/legal/tdmrep-license
- DOI
-
- 10.1016/s1470-2045(16)30408-9
- 公開者
- Elsevier BV
この論文をさがす
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 17 (11), 1599-1611, 2016-11
Elsevier BV